Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31080534 | 0.83 | NPC1 (0.61) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL14958421 | 0.82 | APP (0.58) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL24317098 | 0.80 | APP (0.51) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL20657625 | 0.80 | APP (0.51) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL23281510 | 0.80 | PDE2A (0.49) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL20657592 | 0.79 | APP (0.50) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL23277161 | 0.78 | SMN1; SMN2 (0.50) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL6397952 | 0.78 | ALDH1A1 (0.56) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL27996147 | 0.78 | APP (0.58) | APPMAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL20000873 | 0.78 | APP (0.80) | APPMAOBIDO1AGXTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781511-A1 | HYDROXY GROUP PROTECTING AGENT AND HYDROXY GROUP PROTECTION METHOD | National University Corporation Kanazawa University (JP) | 2014-09-24 | — | — | EP | claimed |
| EP-1549645-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | claimed |
| WO-2004031184-A1 | 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| EP-2781511-B1 | HYDROXY GROUP PROTECTING AGENT AND HYDROXY GROUP PROTECTION METHOD | UNIV NAT CORP KANAZAWA (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-2781511-A1 | HYDROXY GROUP PROTECTING AGENT AND HYDROXY GROUP PROTECTION METHOD | National University Corporation Kanazawa University (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110758-A1 | 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors | TIE1, KDR, FLT1 | APP 3720/4885MAOB 1492/4885IDO1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.